ChemPartner Products & Reviews

Our Metabolite Identification service for peptides utilizes HRMS to characterize peptide metabolism (e.g., hydrolysis, oxidation, glucuronidation). The assay identifies and semi-quantifies metabolites in plasma/tissues, enabling ADME profiling (clearance, bioavailability), toxicity screening (reactive metabolites) and peptide optimization (PK/PD enhancement). Integrated with preclinical data, it supports metabolically stable p…

Our Comprehensive In Vitro Proarrhythmia Assay (CiPA) service assesses proarrhythmic potential of compounds beyond hERG inhibition, integrating effects on multiple cardiac ion channels and human iPSC-derived cardiomyocytes via patch clamp and multi-well MEA platforms. Aligned with FDA's CiPA initiative and ICH E14/S7B guidelines, it predicts QT prolongation and TdP risks for enhanced specificity in early drug safety evaluation…

Our Protein Binding Platform assesses drug-protein interactions using equilibrium dialysis and ultracentrifugation methods to determine unbound fractions and distribution in biological samples including plasma, blood, tissues, and cells. This essential ADME service evaluates reversible drug transfer between compartments, providing insights into pharmacokinetics, bioavailability, and potential interactions.

Our hERG Safety Screening service employs the Synchropatch-384 automated patch clamp system to assess compound effects on the hERG potassium channel. This high-throughput assay detects inhibitors that may prolong QT intervals and cause arrhythmias, aiding early drug safety evaluation. With precise data under physiological conditions, it supports regulatory compliance to advance safer therapeutics. 

Our Metabolite Identification service employs HRMS /LC-MS/MS to decode degradation pathways of antisense oligonucleotides (ASOs), siRNAs, and modified variants, identifying chain-shortened metabolites (5’/3’ cleavage), phosphorothioate changes (desulfurization, inversion) and base/nucleotide alterations (deamination/depurination). Through plasma/tissue/cell analysis, we reveal metabolic stability, biodistribution, and exonucle…

Our Metabolite Identification service for Antibody-Drug Conjugates (ADCs) applies immuno-capture and HRMS to detect payload-containing catabolites, linker cleavages, and biotransformations in biological samples. This targeted assay quantifies free payloads, metabolites, and intact conjugates, assessing stability and off-target risks. Essential for ADC development, it informs payload design and pharmacokinetics, ensuring compli…

Our Cassette and Discrete PK Study service evaluates pharmacokinetic profiles of small molecules in key preclinical species: rat, mouse, dog, and monkey. Using cassette dosing for high-throughput screening of multiple compounds simultaneously and discrete dosing for precise individual assessments for ADME parameters. This aids in early drug optimization, predicting human PK, and ensuring regulatory compliance for safer candida…